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Estimated Quality of Life and Economic Outcomes
AssociatedWith 12 Cervical Cancer Screening Strategies
A Cost-effectiveness Analysis
George F. Sawaya, MD; Erinn Sanstead, MPH; Fernando Alarid-Escudero, PhD; Karen Smith-McCune, MD, PhD;
Steven E. Gregorich, PhD; Michael J. Silverberg, PhD, MPH;Wendy Leyden, MPH; Megan J. Huchko, MD, MPH;
Miriam Kuppermann, PhD, MPH; Shalini Kulasingam, PhD
IMPORTANCE Many cervical cancer screening strategies are now recommended in the United
States, but the benefits, harms, and costs of each option are unclear.
OBJECTIVE To estimate the cost-effectiveness of 12 cervical cancer screening strategies.
DESIGN, SETTING, AND PARTICIPANTS The cross-sectional portion of this study enrolled a
convenience sample of 451 English-speaking or Spanish-speaking women aged 21 to 65 years
from September 22, 2014, to June 16, 2016, identified at women's health clinics in San
Francisco. In this group, utilities (preferences) were measured for 23 cervical cancer
screening–associated health states and were applied to a decisionmodel of type-specific
high-risk human papillomavirus (hrHPV)–induced cervical carcinogenesis. Test accuracy
estimates were abstracted from systematic reviews. The evaluated strategies were cytologic
testing every 3 years for women aged 21 to 65 years with either repeat cytologic testing in
1 year or immediate hrHPV triage for atypical squamous cells of undetermined significance
(ASC-US), cytologic testing every 3 years for women age 21 to 29 years followed by cytologic
testing plus hrHPV testing (cotesting), or primary hrHPV testing alone for women aged 30 to
65 years. Screening frequency, abnormal test result management, and the age to switch from
cytologic testing to hrHPV testing (25 or 30 years) were varied. Analyses were conducted
from both the societal and health care sector perspectives.
MAIN OUTCOMES ANDMEASURES Utilities for 23 cervical cancer screening–associated health
states (cross-sectional study) and quality-adjusted life-years (QALYs) and total costs for
each strategy.
RESULTS Utilities were measured in a sociodemographically diverse group of 451 women
(mean [SD] age, 38.2 [10.7] years; 258 nonwhite [57.2%]). Cytologic testing every 3 years
with repeat cytologic testing for ASC-US yielded themost lifetime QALYs and conferredmore
QALYs at higher costs ($2166 per QALY) than the lowest-cost strategy (cytologic testing every
3 years with hrHPV triage of ASC-US). All cytologic testing plus hrHPV testing (cotesting) and
primary hrHPV testing strategies provided fewer QALYs at higher costs. Adding indirect costs
did not change the conclusions. In sensitivity analyses, hrHPV testing every 5 years with
genotyping triage beginning at age 30 years was the lowest-cost strategy when hrHPV test
sensitivity was markedly higher than cytologic test sensitivity or when hrHPV test cost was
equated to the lowest reported cytologic test cost ($14).
CONCLUSIONS AND RELEVANCE Cytologic testing every 3 years for women aged 21 to 29 years
with either continued cytologic testing every 3 years or switching to a low-cost hrHPV test
every 5 years confers a reasonable balance of benefits, harms, and costs. Comparative
modeling is needed to confirm the association of these novel utilities with cost-effectiveness.
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A n estimated 13 240 women in the United States re-ceived a diagnosis of cervical cancer in 2018, and 4170died from the disease.1 Although large declines in cer-
vical cancer incidence andmortality in the United States have
accompaniedwidespreadscreeningwithcervicalcytologic test-
ing, screening options have greatly expanded beyond cyto-
logic testingalone. In2012,majorguidelinegroups intheUnited
Statesendorsed4cervicalcancerscreeningstrategiesforwomen
aged21 to65years: cervical cytologic testingevery3yearswith
2 options for managing atypical squamous cells of undeter-
mined significance (ASC-US), and cervical cytologic testing
every 3 years for women aged 21 to 29 years followed by cyto-
logic testing plus testing for high-risk human papillomavirus
(hrHPV) every 5 years for women aged 30 to 65 years with
2 options for managing those with normal cytologic test
results and positive results of hrHPV testing.2-4
In 2014, the US Food and Drug Administration approved
a hrHPV test for primary cervical cancer screening in women
aged 25 years or older. The American College of Obstetricians
and Gynecologists stated that this strategy could be consid-
ered as an alternative to current cytologic test–based screen-
ing methods5 and recommended that interim guidance pub-
lished by the Society of Gynecologic Oncology be followed
regarding its use; these guidelines recommended that screen-
ing begin at age 25 years, that rescreening occur “no sooner
than every 3 years”6(p334) and that women with positive
results of hrHPV tests be managed based on HPV genotyping
results and, in some cases, cytologic test results.
In August 2018, the US Preventive Services Task Force
endorsed primary hrHPV testing alone performed at 5-year
intervals beginning at age 30 years as a preferred screening
strategy7 along with cytologic testing at 3-year intervals for
women aged 21 to 65 years. The group continued to recom-
mend cotesting (cytologic testing plus hrHPV testing) for
women aged 30 to 65 years as an alternative strategy.
With various possible test combinations, screening fre-
quencies, and ages to switch from one screening strategy to
another, many different cervical cancer screening strategies
arenowbeingrecommended in theUnitedStates.Tohelp iden-
tify which strategies might constitute high-value care, some
groupshave recommended that cost-effectivenessanalysesbe
performed.2 Prior analyses have been hampered by the lack
of a comprehensive, population-derived set of process utili-
ties (preferences) that capture important quality of life out-
comes anticipated throughout the contemporary screening
process.8,9 In an effort to contribute to policy discussions re-
garding high-value cervical cancer screening, we estimated
qualityof life andeconomicoutcomesassociatedwith 12 strat-
egies by measuring women’s preferences and incorporating
them into a cost-effectiveness analysis.
Methods
UtilityMeasurement
Weconducted4focusgroupstoaid inconstructingscenarios for
healthstatesassociatedwithcervical cancerscreening (eTable 1
in the Supplement). A sociodemographically diverse group of
English-speakingorSpanish-speakingwomenaged21to65years
was then recruited from 2women’s health clinics in San Fran-
cisco,California,betweenSeptember22,2014,andJune16,2016.
Thesociodemographicandclinicalcharacteristicsof thesample
are ineTable2 in theSupplement.Thesewomenwereenrolled
inacross-sectionalstudyconsistingofa50-minute, face-to-face
interview during which they completed an interviewer-
administeredquestionnaireandvieweda7-minuteeducational
video.Usingacomputerizedtool,preferenceswereelicitedfrom
participantsusing the time tradeoffmethod10,11 andwereused
togenerateutilitiesfor23healthstates.Topreventfatigue,health
statesweregroupedinto3setsof7or8;eachparticipantwasran-
domly assigned by computer to assess 2 of the 3 sets. Tomini-
mize possible effects of the order inwhich scenarioswere pre-
sented,wealso randomized the setpresentationorder. Prior to
viewingtheeducationalmaterialsandperformingthepreference
elicitation exercise, the first 262 participantswere asked to se-
lect a preferred screening strategy; after the exercisewas com-
pleted, they were again asked to select a preferred strategy
(eTable 3 in the Supplement). TheUniversity of California, San
Francisco and Zuckerberg San Francisco General Hospital
Institutional Review Boards approved this study, and written
informedconsentwasobtainedfromtheparticipants.Detailsare
in eAppendices 1, 2, and 3 in the Supplement.
Model Overview, Inputs, and Assumptions
We constructed an HPV type-specific Markov decision model
usingdataon thenaturalhistoryofHPVandcervicalneoplasia.
The model was constructed using TreeAge Pro 2017 (TreeAge
Software Inc), andR,version3.5.0 (RFoundation forStatistical
Computing).12 The natural historymodel simulated a birth co-
hortofwomenataverageriskofdevelopingcervical cancer (not
immune-compromisedandnotvaccinatedagainstHPV). In the
model, the transition probabilities between health stateswere
HPV type–specific (eFigure 1 in the Supplement). To fully cap-
turechanges inhealthstatesassociatedwithscreening,weused
a 1-yearMarkov cycle length.
The cohort started at age 10yearswithnoexistingHPV in-
fections and was followed over a lifetime (until death or age
Key Points
Question After incorporating women’s preferences into a
cost-effectiveness analysis, what are the estimated quality of life
and economic outcomes associated with cervical cancer screening
strategies currently recommended in the United States?
Findings Of 12 strategies evaluated in a cost-effectiveness model,
cytologic testing every 3 years for women aged 21 to 29 years with
either continued triennial cytologic testing or switching to a
low-cost high-risk human papillomavirus test every 5 years from
age 30 to 65 years conferred a reasonable balance of benefits,
harms, and costs from both a societal and health care sector
perspective.
Meaning Cytologic testing every 3 years and low-cost high-risk
human papillomavirus testing every 5 years bothmay be
considered reasonable cervical cancer screening options for
women aged 30 to 65 years.
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100 years). Every year, women were at risk of becoming in-
fectedwithHPV 16 or 18 or other hrHPV types (eTable 4 in the
Supplement). Women could clear their infections, stay in-
fected, or progress to cervical intraepithelial neoplasia, a pre-
cancerous lesion. Cervical intraepithelial neoplasia could re-
gress, persist, or progress to higher grades or cancer. Cervical
intraepithelial neoplasia grade 1was includedas ahealth state
because currentmanagement guidelines endorse treatment if
these lesions persist.13 Women with cancer could have their
cancerdetectedbysymptomsas thestageprogressedandwere
at risk of cancer death (eTable 5 in the Supplement). Women
were also at risk of age-specific causes of death and of under-
going hysterectomy for noncancerous conditions.
We used Bayesian calibration methods to estimate the
parameters of the natural history by matching model-
predicted outcomes with calibration targets (eFigures 2-4 in
the Supplement). Validation was by comparison with 2
sources: outcomes from a recent randomized trial of hrHPV
testing compared with cytologic testing14 and Surveillance,
Epidemiology, and End Results (SEER) data15 (eFigures 5-7 in
the Supplement). Details are in eAppendices 4, 5, and 6 and
eTable 6 in the Supplement.
Screening Strategies and Test Accuracy Estimates
We evaluated 12 strategies: cytologic testing every 3 years for
women aged 21 to 65 years with either repeat cytologic test-
ing in 1 year or immediate hrHPV triage for women with
ASC-US; cytologic testing every 3 years for women aged 21 to
29 years followed by cotesting forwomen aged 30 to 65 years
with either repeat cotesting in 1 year or immediate genotyp-
ing triage for women with normal cytologic test results and
positive hrHPV test results; cytologic testing every 3 years for
women aged 21 to 29 years followed by primary hrHPV test-
ing alone every 3 years or every 5 years for women aged 30 to
65 years with either immediate cytologic testing triage for
women with positive hrHPV test results or immediate geno-
typing triage forwomenwith positive hrHPV test resultswith
additional cytologic testing triage of women with positive
hrHPV test results and negative genotyping results. In strate-
gies switching fromcytologic testing tohrHPV testing,wealso
evaluated switching at aged25 years insteadof 30years (eAp-
pendix 7 and eTable 7 in the Supplement).
For all cotesting and primary hrHPV testing strategies,
women underwent cytologic screening prior to beginning
hrHPV testing.We included annual cytologic testing as an ad-
ditional comparator because it is a screening strategy still pre-
ferred bymanyUSwomen.16,17Management of abnormal test
results and cervical intraepithelial neoplasia treatment were
programmed in the model to reflect the complexity of cur-
rent American Society of Colposcopy and Cervical Pathology
guidelines13 (eTables 7 and 8, eAppendix 8, and eFigures 8-14
in theSupplement).Weassumed that allwomenadheredwith
screening, follow-up and treatment.
In primary analyses, estimates of screening test accuracy
(sensitivity and specificity) were abstracted from recent sys-
tematic reviews, including a 2017 Cochrane review
(Table 1).18-25 We used cervical intraepithelial neoplasia
grade 2 as defining disease because treatment is recom-
mended for most women in the United States with this
lesion.13 In sensitivity analyses, we used accuracy estimates
from a multicentered, United States–based study that
enrolled more than 47000 women (the Addressing the Need
for Advanced HPV Diagnostics study [ATHENA])26; we used
unadjusted accuracy estimates and those adjusted for verifi-
cation bias. We used separate summary accuracy estimates
for tests applied in surveillance21,22 and posttreatment
follow-up.23 Clinical algorithms and utility maps are in eFig-
ures 8-14 in the Supplement.
Costs
We incorporated direct medical costs into our model, re-
ported in 2016 US dollars and accounting for medical infla-
tion. Direct costs associated with screening, diagnosis, and
treatment were based on Medicare reimbursement rates
(Table 1).18-25 Costs for cancer, including cancer death, were
based on SEER-Medicare claims data.25 In sensitivity analy-
ses,we included indirect nonmedical costs, including time for
patient travel, waiting, and examination.27 In the absence of
published studies on the indirect costs for cervical cancer,we
used costs for uterine cancer.28
Analysis
The primary outcomes were lifetime costs in 2016 US dollars
andquality-adjusted life-years (QALYs) for each strategy, both
discounted at an annual rate of 3%. Each utility was mapped
to an outcome for a specific strategy that would occur during
a 1-year period (eFigures 8-14 in the Supplement); only 1 util-
ityperuniqueoutcomewasapplied.As recommended,29 cost-
effectivenessanalyseswereconductedfrombothasocietal and
health care sector perspective. Incremental cost-effective-
ness ratios were calculated by dividing the additional cost by
the additional health benefit of a specific strategy compared
with the next less costly, nondominated strategy.
Sensitivity Analyses: Deterministic
We performed deterministic sensitivity analyses to examine
the independent effect of the following on total costs, QALYs,
andincrementalcost-effectiveness ratios:adding indirectcosts,
substituting ATHENA test accuracy estimates, and equating
hrHPV test cost with the reported lower bound for the cost of
a cytologic test ($14).Weexplored the result of substitutingac-
curacyestimates in theprimaryscreeningsettingwiththehigh-
est summary specificity estimates reported for hrHPV testing
(Table 1)18-25;becauseofa lackofdirectevidence regardinghow
this change in specificity affects accuracy estimates for co-
testingandprimaryhrHPVtestingwithgenotypingtriage, these
strategies were excluded from this model. To explore the in-
dependent effect of utilities on our results, we removed utili-
ties stepwise by the categories defined in Table 118-25 (screen-
ing, then surveillance, then false-positive testing, then
treatment and cancers).
Sensitivity Analyses: Probabilistic
Toaccountformodel inputparameteruncertainty,werandomly
sampledvalues fromparameterdistributions.For thecalibrated
parameters, we sampled from the posterior distribution
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Table 1. Model Inputs for Utilities, Test Accuracy Estimates, and Costs
Variable Value Source
Screening results, utility, mean (95% CI)a
Normal cytologic test 0.97294 (0.96343-0.98103) Current study
Normal cytologic test in past; no testing this year 0.97643 (0.96818-0.98338) Current study
Normal cytologic test, negative hrHPV test 0.97061 (0.96224-0.97819) Current study
Normal cytologic test, negative hrHPV test in
past; no testing this year
0.96465 (0.95281-0.97444) Current study
Negative hrHPV test 0.96017 (0.94648-0.97146) Current study
Negative hrHPV test in past; no testing this year 0.96096 (0.94673-0.97299) Current study
ASC-US cytologic test, negative hrHPV test
in past; no testing this year
0.94564 (0.93220-0.95896) Current study
Simple hysterectomy in the past; no testing
this year
0.86506 (0.83926-0.88782) Current study
Surveillance, mean (95% CI)a
ASC-US cytologic test; repeat cytology in 1 y 0.94740 (0.93410-0.95937) Current study
ASC-US cytologic test, negative hrHPV test 0.94405 (0.93116-0.95633) Current study
Normal cytologic test, positive hrHPV test;
repeat both in 1 y
0.93408 (0.91845-0.94873) Current study
CIN2, no treatment; repeat colposcopy 0.91417 (0.89429-0.93204) Current study
False-positive test results, mean (95% CI)a
Abnormal cytologic test, normal colposcopy 0.96108 (0.94932-0.97167) Current study
Abnormal cytologic test, positive hrHPV test,
normal colposcopy
0.94492 (0.93062-0.95815) Current study
Positive hrHPV test, normal colposcopy 0.94238 (0.92658-0.95825) Current study
Normal cytologic test, persistently positive
hrHPV test, normal colposcopy
0.93713 (0.92110-0.95177) Current study
Treatment, mean (95% CI)a
Ablative therapy 0.94993 (0.93626-0.96174) Current study
Excisional therapy 0.91356 (0.89322-0.93178) Current study
Simple hysterectomy 0.83865 (0.81238-0.86427) Current study
Early-stage cervical cancer, radical hysterectomy 0.78385 (0.74342-0.82457) Current study
Early-stage cervical cancer, radical hysterectomy
in past; no testing this year
0.77935 (0.73675-0.81643) Current study
Advanced-stage cervical cancer, radiotherapy
and chemotherapy
0.72767 (0.68368-0.77222) Current study
Advanced-stage cervical cancer, radiotherapy
and chemotherapy in past; no testing this year
0.73586 (0.68869-0.78337) Current study
Test Accuracy Estimates
Screening setting, primary estimates,
sensitivity/specificitya
Cytologic testing 0.755 (range, 0.43-0.96)/
0.919 (range, 0.73-0.98)
Koliopoulos et al,18 2017
hrHPV testing 0.926 (range, 0.61-1.00)/
0.893 (range, 0.58-0.97)
Koliopoulos et al,18 2017
Cytologic testing plus hrHPV testing (cotesting) 0.937 (range, 0.75-1.00)/
0.858 (range, 0.32-0.93)
Li et al,19 2016
Screening setting, secondary estimates (ATHENA,
adjusted for verification bias), sensitivity/specificity
Cytologic testing 0.353/0.941 FDA,20 2014
hrHPV testing 0.613/0.905 FDA,20 2014
Cytologic testing plus hrHPV testing (cotesting) 0.649/0.868 FDA,20 2014
Screening setting, secondary estimates (ATHENA,
unadjusted), sensitivity/specificityb
Cytologic testing 0.552/0.950 FDA,20 2014
hrHPV testing 0.945/0.921 FDA,20 2014
Cytologic testing plus hrHPV testing (cotesting) 1.0/0.890 FDA,20 2014
Screening setting, high-specificity estimate
for hrHPV testing
0.927/0.933 Koliopoulos et al,18 2017
Surveillance setting, sensitivity/specificity
Cytologic testing 0.818/0.576 Arbyn et al,21 2004
Cytologic testing plus hrHPV testing (cotesting) 0.997/0.413 Arbyn et al,22 2015
(continued)
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obtained from the Bayesian calibration approach (eAppendix
5 in theSupplement). In total,weperformed 10000 iterations
ofMonteCarlo simulations to evaluate the effect of varying all
model inputs simultaneously for each strategy (ranges in
Table 118-25) on cost-effectiveness results.
Results
Wemeasuredutilities (Table 1) in451women.Theirmean (SD)
agewas 38.2 (10.7) years, 258 (57.2%)were nonwhite, and 151
(35.7%) had less than a college degree (eTable 2 in the Supple-
ment).Estimated lifetimescreeningoutcomesper1000women
demonstratedmore false-positive test results associatedwith
hrHPV test–based strategieswith concurrent lower cancer in-
cidence (Table 2). Cancermortality ranged from0.9 to 1.4 per
1000 women who underwent screening compared with 19.0
per 1000 women who did not undergo screening.
Screening was cost-saving compared with no screening
($1267-$2577perwomanvs $2891perwoman). Cytologic test-
ing every 3 years with repeat cytologic testing for ASC-US
yielded the most lifetime QALYs (28.91174) (Table 3). Cyto-
logic testingevery3yearswithhrHPVtriageofASC-USwas the
lowest-cost strategy ($1267 per woman), and cytologic test-
ing every 3yearswith repeat cytologic testing forASC-US con-
ferred more QALYs at higher costs ($2166 per QALY). Cotest-
ingandprimaryhrHPVtestingprovided fewerQALYsathigher
costs (ie, were dominated). Annual cytologic testing was the
most costly strategy but provided fewerQALYs thandid cyto-
logic testing every 3 years (lifetime costs, $2577; QALYs,
28.80491).
Sensitivity Analyses
Adding indirect costs did not change our conclusions about
cost-effectiveness (Table 3). When the costs of hrHPV testing
were equated to the lower bound of cytologic testing ($14),
hrHPV testing every 5yearswithgenotyping triage forwomen
with positive hrHPV test results and additional cytologic tri-
age of women with positive hrHPV test results and negative
genotyping- results beginning at age 30 yearswas the lowest-
cost strategy ($1183).AdditionalQALYsathighercostswerecon-
ferred by cytologic testing every 3 years with hrHPV triage of
ASC-US ($708perQALY) and furtherwith cytologic testing ev-
ery 3 years with repeat cytologic testing in 1 year for ASC-US
($2590 per QALY).
When we substituted ATHENA test accuracy estimates
adjusted for verification bias in which hrHPV test sensitivity
was markedly greater than that of cytologic testing (0.649 vs
0.313), hrHPV testing every 5 years with genotyping triage
for women with positive hrHPV test results and additional
cytologic triage of women with positive hrHPV test results
and negative genotyping results beginning at age 30 years
was the lowest-cost strategy; additional QALYs at higher
costs were conferred by cytologic testing every 3 years with
hrHPV triage of ASC-US ($715 per QALY) and further with
cytologic testing every 3 years with repeat cytologic testing
for ASC-US ($2446 per QALY). Conclusions were similar
when we used unadjusted ATHENA accuracy estimates
(eAppendix 9 and eTable 9 in the Supplement). When we
substituted a high-specificity estimate for hrHPV testing
(0.933),18 hrHPV testing every 5 years with cytologic triage
beginning at age 30 years was the least costly strategy ($1230
per woman); additional QALYs at higher costs could be
achieved with cytologic testing every 3 years with hrHPV tri-
age of ASC-US ($488 per QALY) and further with cytologic
testing every 3 years with repeat cytologic testing in 1 year
for ASC-US ($2166 per QALY; eTable 9 in the Supplement).
Although utilities for health states involving hrHPV test-
ing for screening and surveillance were generally lower than
those for cytologic testing (Table 1), removal of these utilities
Table 1. Model Inputs for Utilities, Test Accuracy Estimates, and Costs (continued)
Variable Value Source
Posttreatment follow-up setting,
sensitivity/specificity
Cytologic testing 0.79/0.81 Kocken et al,23 2012
Cytologic testing plus hrHPV testing (cotesting) 0.95/0.67 Kocken et al,23 2012
Service, Test, and Treatment, Cost (Range), $a
Office visit 73 (47-92) CMS24
Cytologic testing 25 (14-28) CMS24
hrHPV testing 44 (26-47) CMS24
Colposcopy and biopsy 226 (166-284) CMS24
Cryosurgery 145 (120-230) CMS24
Loop excision 524 (387-1636) CMS24
Cold knife cone biopsy 1569 (1449-1701) CMS24
Cancer care, first year
Age <65 y 64 742 (NA) Mariotto et al,25 2011
Age ≥65 y 53 950 (NA) Mariotto et al,25 2011
Cancer care, ongoing 1702 (NA) Mariotto et al,25 2011
Cancer care, last year of life
Age <65 y 141 201 (NA) Mariotto et al,25 2011
Age ≥65 y 94 134 (NA) Mariotto et al,25 2011
Abbreviations: ASC-US, atypical
squamous cells of undetermined
significance; ATHENA, Addressing
the Need for Advanced HPV
Diagnostics study; CIN2, cervical
intraepithelial neoplasia grade 2;
CMS, Centers for Medicare &
Medicaid Services; FDA, US Food and
Drug Administration; hrHPV, high-risk
human papillomavirus; NA, not
available.
a Range used in probabilistic
sensitivity analysis.
b Restricted to verified cases of CIN2
or worse and assuming womenwith
normal cytologic test results and
negative hrHPV test results did not
have CIN2 or worse.
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did not change our conclusions about cost-effectiveness; the
incremental cost-effectiveness ratio of cytologic testing ev-
ery 3 years with repeat cytologic testing in 1 year for ASC-US
compared with cytologic testing every 3 years with hrHPV
triageofASC-US increased from$2166perQALY to $21 795per
QALY. Additionally removing utilities associated with false-
positive test results suggested that cytologic testing every 3
years with hrHPV triage of ASC-US dominated all other
Table 2. Estimated Cervical Cancer Screening Outcomes per 1000WomenOver a Lifetime, by Source of Test Accuracy Estimates
Screening Strategy
Screening, Surveillance, and Treatment
Outcomes, No. Cervical Cancer Outcomes, No.
Colposcopies
False-Positive
Test Resultsa Treatmentsb
Stage
1
Stage
≥2
All
Stages
Cancer
Deaths
No screening NA NA NA 14.38 15.81 30.19 19.02
Primary Analysis: Using Accuracy Estimates From Systematic Reviews and Meta-analyses
Cytologic testing every 3 y
Repeat cytologic test in 1 y for ASC-US 1870 1223 440 1.74 0.67 2.41 1.44
hrHPV triage for ASC-US 2074 1429 421 1.58 0.64 2.22 1.30
Cytologic testing and hrHPV test (cotesting) every 5 y
Repeat in 1 y for normal cytologic test results and positive hrHPV test results 2696 2125 584 1.56 0.63 2.19 1.29
Genotyping triage for normal cytologic test results and positive hrHPV test
results
2879 2294 585 1.53 0.62 2.15 1.27
hrHPV testing every 3 y, cytologic triage for positive hrHPV test results
Begin at age 25 y 2734 2208 603 1.22 0.36 1.58 0.94
Begin at age 30 y 2707 2147 570 1.33 0.38 1.71 1.03
hrHPV testing every 5 y, cytologic triage for positive hrHPV test results
Begin at age 25 y 2179 1708 517 1.79 0.54 2.33 1.41
Begin at age 30 y 2176 1654 495 1.81 0.55 2.36 1.42
hrHPV testing every 3 y, genotyping triage for positive hrHPV test results plus
cytologic triage if positive hrHPV test results and negative genotyping
Begin at age 25 y 3090 2508 599 1.19 0.48 1.67 0.097
Begin at age 30 y 3009 2416 568 1.29 0.48 1.77 1.0
hrHPV testing every 5 y, genotyping triage for positive hrHPV test results plus
cytologic triage if positive hrHPV test results and negative genotyping
Begin at age 25 y 2488 1966 518 1.65 0.55 2.2 1.30
Begin at age 30 y 2425 1874 496 1.69 0.56 2.25 1.34
Secondary Analysis: Using Accuracy Estimates From ATHENA Study, Adjusted for Verification Bias
Cytologic testing every 3 y
Repeat cytologic test in 1 y for ASC-US 1364 963 317 3.98 2.33 6.31 3.52
hrHPV triage for ASC-US 1481 1075 295 3.78 2.33 6.11 3.49
Cytologic testing and hrHPV test (cotesting) every 5 y
Repeat in 1 y for normal cytologic test results and positive hrHPV test results 2282 1911 491 3.14 1.61 4.75 2.56
Genotyping triage for normal cytologic test results and positive hrHPV
test results
2481 2083 492 2.92 1.61 4.53 2.51
hrHPV testing every 3 y, cytologic triage for positive hrHPV test results
Begin at age 25 y 2457 2045 531 2.23 0.88 3.11 1.78
Begin at age 30 y 2379 1983 489 2.64 1.12 3.76 2.09
hrHPV testing every 5 y, cytologic triage for positive hrHPV test results
Begin at age 25 y 1913 1559 439 3.28 1.60 4.88 2.85
Begin at age 30 y 1854 1498 407 3.55 1.77 5.32 3.08
hrHPV testing every 3 y, genotyping triage for positive hrHPV test results plus
cytologic triage if positive hrHPV test results and negative genotyping
Begin at age 25 y 2769 2307 528 2.10 0.97 3.07 1.74
Begin at age 30 y 2642 2219 486 2.51 1.16 3.67 2.03
hrHPV testing every 5 y, genotyping triage for positive hrHPV test results plus
cytologic triage if positive hrHPV test results and negative genotyping
Begin at age 25 y 2177 1780 439 2.97 1.52 4.49 2.58
Begin at age 30 y 2066 1687 408 3.26 1.69 4.95 2.82
Abbreviations: ASC-US, atypical squamous cells of undetermined significance;
ATHENA, Addressing the Need for Advanced HPV Diagnostics study;
hrHPV, high-risk human papillomavirus; NA, not applicable.
a Positive test results that lead to colposcopy in which no cervical intraepithelial
neoplasia grade 2 or worse is found.
bCryosurgeries, loop excisions, or cone biopsies.
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Table 3. Estimated Lifetime Costs, QALYs, and ICERs
Screening Strategy Cost, $ QALYs ICER, $/QALYsa
Primary Analysis: Using Accuracy Estimates From Systematic Reviews and Meta-analyses
Cytologic testing every 3 y, hrHPV triage for ASC-US 1267 28.84109 0
hrHPV testing every 5 y, genotyping triage for positive hrHPV test results
plus cytologic triage if positive hrHPV test results and negative
genotyping, begin at age 30 y
1303 28.76624 Dominated
hrHPV testing every 5 y, cytologic triage for positive hrHPV test results,
begin at age 30 y
1311 28.75601 Dominated
hrHPV testing every 5 y, genotyping triage for positive hrHPV test results
plus cytologic triage if positive hrHPV test results and negative
genotyping, begin at age 25 y
1355 28.73210 Dominated
hrHPV testing every 5 y, cytologic triage for positive hrHPV test results,
begin at age 25 y
1359 28.72099 Dominated
Cytologic testing every 3 y, repeat cytologic testing in 1 y for ASC-US 1420 28.91174 2166
Cytologic and hrHPV testing (cotesting) every 5 y
Repeat cotesting in 1 y for normal cytologic test results and positive
hrHPV test results
1480 28.81260 Dominated
Genotyping triage for normal cytologic test results and positive hrHPV
test results
1491 28.81007 Dominated
hrHPV testing every 3 y, genotyping triage for positive hrHPV test results
plus cytologic triage if positive hrHPV test results and negative
genotyping, begin at age 30 y
1492 28.73761 Dominated
hrHPV testing every 3 y, cytologic triage for positive hrHPV test results,
begin at age 30 y
1507 28.71668 Dominated
hrHPV testing every 3 y, genotyping triage for positive hrHPV test results
plus cytologic triage if positive hrHPV test results and negative
genotyping, begin at age 25 y
1589 28.71363 Dominated
hrHPV testing every 3 y, cytologic triage for positive hrHPV test results,
begin at age 25 y
1600 28.68792 Dominated
Secondary Analysis: Using Accuracy Estimates From ATHENA Study, Adjusted for Verification Bias
hrHPV testing every 5 y, genotyping triage for positive hrHPV test results
plus cytologic triage if positive hrHPV test results and negative
genotyping
Begin at age 30 y 1482 28.74043 0
Begin at age 25 y 1503 28.71014 Dominated
hrHPV testing every 5 y, cytologic triage for positive hrHPV test results
Begin at age 30 y 1515 28.73124 Dominated
Begin at age 25 y 1531 28.69984 Dominated
Cytologic testing every 3 y, hrHPV triage for ASC-US 1537 28.81736 715
hrHPV testing every 3 y, genotyping triage for positive hrHPV test results
plus cytologic triage if positive hrHPV test results and negative
genotyping, begin at age 30 y
1591 28.71827 Dominated
hrHPV testing every 3 y, cytologic tests for positive hrHPV test results,
begin at age 30 y
1617 28.69958 Dominated
Cytologic and hrHPV testing (cotesting) every 5 y
Repeat cotesting in 1 y for normal cytologic test results and positive
hrHPV test results
1636 28.79016 Dominated
Genotyping for normal cytologic test results and positive hrHPV
test results
1642 28.78897 Dominated
hrHPV testing every 3 y, genotyping triage for positive hrHPV test results
plus cytologic triage if positive hrHPV test results and negative
genotyping, begin at age 25 y
1645 28.69942 Dominated
hrHPV testing every 3 y, cytologic triage for positive hrHPV test results,
begin at age 25 y
1669 28.67583 Dominated
Cytologic testing every 3 y, repeat cytologic testing in 1 y for ASC-US 1717 28.89095 2446
Sensitivity Analysis: Adding in Indirect Costs
Cytologic testing every 3 y, hrHPV triage for ASC-US 1581 28.84109 0
hrHPV testing every 5 y, genotyping triage for positive hrHPV test results
plus cytologic triage if positive hrHPV test results and negative
genotyping, begin at age 30 y
1604 28.76624 Dominated
hrHPV testing every 5 y, cytologic triage for positive hrHPV test results,
begin at age 30 y
1612 28.75601 Dominated
hrHPV testing every 5 y, genotyping triage for positive hrHPV test results
plus cytologic triage if positive hrHPV test results and negative
genotyping, begin at age 25 y
1666 28.73210 Dominated
(continued)
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strategies.When all utilitieswere removed, hrHPV testing ev-
ery 3 years with genotyping triage for women with positive
hrHPV test results and additional cytologic triage of women
with positive hrHPV test results and negative genotyping re-
sults beginning at age 25 years conferredmore life-years than
did cytologic testing with hrHPV triage of ASC-US (29.54523
vs 29.54286 life-years; $135865 per life-year; Figure 1).
Probabilistic sensitivity analyses showed that at cost-
effectiveness thresholds of $50000 per QALY, $100000 per
QALY and $150000 per QALY, cytologic testing every 3 years
with repeat cytologic testing for ASC-USwas cost-effective in
95% to 96% of iterations (Figure 2). Cytologic testing with
hrHPV triage ofASC-US every 3 yearswas cost-effective in 4%
to5%of iterationsandprimaryhrHPVtestingevery5yearswas
cost-effective in0.01%to0.04%of iterations.BeginninghrHPV
testing prior to age 30 years, performing hrHPV testing every
3 years, and cotesting were cost-effective in 0% of iterations
(ie, not cost-effective).
Discussion
Of 12 strategies evaluated, our findings suggest that cytologic
testing every 3years forwomenaged21 to 29yearswith either
continuedcytologic testingevery3yearsor switching toa low-
cost hrHPV test every 5 years from age 30 to 65 years confers
a reasonable balance of benefits, harms, and costs from both
a societal and health care sector perspective. Cytologic test-
ing plus hrHPV testing (cotesting) did not appear to be cost-
effective under any condition we evaluated. Both the Ameri-
can College of Obstetricians and Gynecologists and the
AmericanCancer Society consider cotesting thepreferred cer-
vical cancer screening strategy, and the US Preventive Ser-
vices Task Force considers it an alternative strategy. Our find-
ingschallenge theseendorsements.Furthermore,ouranalyses
suggest that it isnot cost-effective tobeginprimaryhrHPVtest-
ingprior toage30years, toperformhrHPVtestingevery3years,
Table 3. Estimated Lifetime Costs, QALYs, and ICERs (continued)
Screening Strategy Cost, $ QALYs ICER, $/QALYsa
hrHPV testing every 5 y, cytologic triage for positive hrHPV test results,
begin at age 25 y
1668 28.72099 Dominated
Cytologic testing every 3 y, repeat cytologic testing in 1 y for ASC-US 1806 28.91174 3184
Cytologic and hrHPV testing (cotesting) every 5 y
Repeat cotesting in 1 y for normal cytologic results and positive hrHPV
test results
1821 28.81260 Dominated
Genotyping triage for normal cytologic results and positive hrHPV
test results
1835 28.81007 Dominated
hrHPV testing every 3 y, genotyping triage for positive hrHPV test results
plus cytologic triage if positive hrHPV test results and negative
genotyping, begin at age 30 y
1844 28.73761 Dominated
hrHPV testing every 3 y, cytologic triage for positive hrHPV test results,
begin at age 30 y
1861 28.71668 Dominated
hrHPV testing every 3 y, genotyping triage for positive hrHPV test results
plus cytologic triage if positive hrHPV test results and negative
genotyping, begin at age 25 y
1963 28.71363 Dominated
hrHPV testing every 3 y, cytologic triage for positive hrHPV test results,
begin at age 25 y
1974 28.68792 Dominated
Sensitivity Analysis: Using a Low-Cost hrHPV Test ($14)
hrHPV testing every 5 y, genotyping triage for positive hrHPV test results
plus cytologic triage if positive hrHPV test results and negative
genotyping, begin at age 30 y
1183 28.76624 0
hrHPV testing every 5 y, cytologic triage for positive hrHPV test results,
begin at age 30 y
1188 28.75601 Dominated
hrHPV testing every 5 y, genotyping triage for positive hrHPV test results
plus cytologic triage if positive hrHPV test results and negative
genotyping, begin at age 25 y
1210 28.73210 Dominated
hrHPV testing every 5 y, cytologic triage for positive hrHPV test results,
begin at age 25 y
1211 28.72099 Dominated
Cytologic testing every 3 y, hrHPV triage for ASC-US 1236 28.84109 708
hrHPV testing every 3 y, genotyping triage for positive hrHPV test results
plus cytologic triage if positive hrHPV test results and negative
genotyping, begin at age 30 y
1330 28.73761 Dominated
hrHPV testing every 3 y, cytologic triage for positive hrHPV test results,
begin at age 30 y
1335 28.71668 Dominated
Cytologic and hrHPV testing (cotesting) every 5 y, repeat cotesting in 1 y
for normal cytologic results and positive hrHPV test results
1359 28.81260 Dominated
Cytologic and HPV testing (cotesting) every 5 y, genotyping triage for
normal cytologic results and positive hrHPV test results
1370 28.81007 Dominated
hrHPV testing every 3 y, genotyping triage for positive hrHPV test results
plus cytologic triage if positive hrHPV test results and negative
genotyping, begin at age 25 y
1393 28.71363 Dominated
hrHPV testing every 3 y, cytologic triage for positive hrHPV test results,
begin at age 25 y
1393 28.68792 Dominated
Cytologic testing every 3 y, repeat cytologic testing in 1 y for ASC-US 1419 28.91174 2590
Abbreviations: ASC-US, atypical
squamous cells of undetermined
significance; ATHENA, Addressing
the Needs for Advanced HPV
Diagnostics study; hrHPV, high-risk
human papillomavirus;
ICER, incremental cost-effectiveness
ratio; QALY, quality-adjusted
life-years.
a Dominated strategies provide fewer
QALY at greater costs than the
adjacent, nondominated, lower-cost
strategy.
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or to performcytologic testing annually. Comparativemodel-
ing is needed to confirm these findings.
Our sensitivity analyses identified 3 factors that are po-
tentially associatedwith the cost-effectiveness of hrHPV test-
ing: test sensitivity, test specificity, andtest cost.Whenweused
ATHENAestimates inwhichhrHPV test sensitivitywasmark-
edly greater than that of cytologic testing (0.649 vs 0.313),
hrHPV testing every 5yearswithgenotyping triage forwomen
with positive hrHPV test results and additional cytologic tri-
age of women with positive hrHPV test results and negative
genotyping results beginning at age 30 years was the lowest-
cost strategy, suggesting that full-cost hrHPV testing may be
a reasonable approach to screening in some US settings. The
ATHENA estimate for cytologic test sensitivity, however, was
lower than all 15 estimates summarized in the 2017 Cochrane
review18 (range, 0.52-0.94); the generalizability of ATHENA
findings to other screening settings has been questioned.30
Our finding that primaryhrHPV testing every 5 yearswith
cytologic triage is the lowest-cost strategywhen test specific-
ity is relatively highdemonstrates a tangibleway inwhich the
screening processmight be improved; using tests with a rela-
tively lowspecificityoften leads to surveillance, a costlyhealth
Figure 1. Effect of Sequential Utility Removal on Estimated Quality-Adjusted Life-Years Using Accuracy
Estimates From Systematic Reviews andMeta-analyses
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state to which our participants assigned relatively low utili-
ties. Our high-specificity estimate was derived from a hrHPV
test targeting E6 andE7mRNA.18 This analysis, however,was
limitedbyour inability to compareprimaryhrHPVtestingwith
all other 11 strategies. Our sensitivity analysis of hrHPV test
costs demonstrated that the attractiveness of hrHPV testing
could be improved directly by lowering the cost of the test.
We chose the QALY as our primary outcome because it is
awidely recognizedmeasure that combines length of life and
population-derived health-related quality of life in a single
measure.31,32Other recentcost-effectivenessanalyses thathave
foundhrHPV test–based strategies to bemore favorable to cy-
tologic testing–based strategies in US settings have used out-
comesother than theQALY.33,34Other analyseshavebeen lim-
ited by the use of utilities derived from expert panels.35,36
Investigators of a recent randomized clinical trial37 com-
paring2of the12strategiesweevaluated (cytologic testingwith
hrHPV triage of ASC-US vs hrHPV testing with cytologic tri-
age of positive hrHPV tests) stated that the cost-effectiveness
of these strategies would need to be understood. Our cost-
effectiveness analysis suggests that over a lifetime of screen-
ing, cytologic testingevery3yearswithhrHPVtriageofASC-US
dominates hrHPV testing with cytologic triage of positive
hrHPV tests performed either every 3 years or every 5 years
(Table 3).
Limitations and Strengths
Our study has important limitations. Although our partici-
pants were recruited from 2 clinical settings, the preferences
wemeasured may not be generalizable to other populations.
We did not identify any demographic or clinical characteris-
tic bywhich theutilities varied; these analyses, however,may
havebeenunderpowered todetectdifferences (eTables 10and
11 in theSupplement).Despiteprovidingparticipantswithclini-
cal information invisual,written,andaudio formatsalongwith
a research assistant to provide clarifications, we could not be
assured thatparticipantsunderstood the informationor its rel-
evance to the time tradeoff exercise. Our estimates of inci-
dent cancers arehigher than those reported recently,38 aswere
our estimates of cancer deaths, perhaps because of differen-
tial assumptions regarding natural history. Other differences
maybebecauseof the intensitywithwhichwemodeledguide-
line-recommendedsurveillanceandposttreatment follow-up.
We did not consider the projected effect of HPV vaccination
because of limited evidence concerning screening outcomes
among vaccinated women as well as current recommenda-
tions by allmajor guideline groups that vaccinatedwomenbe
screened no differently than unvaccinated women. To allow
comparisonswith outcomes from other studies, we assumed
100%adherence.Howadherenceat thenumerous steps in the
screeningprocessmaydiffer by strategy is uncertain, butmay
affect screening effectiveness. Finally, we used age-specific
transitions tomodel natural history in contrast with time-in-
state dependent transitions,38 highlighting the need to con-
firm our findings using comparative modeling.
Our study also has strengths. Ourmeasurement of a com-
prehensivesetofhealthprocessutilitiesspecific tocervical can-
cer screening in a sociodemographically diverse group of
women allowed comparisons of quality of life outcomes con-
ferred by each and demonstration of the independent effect
of utilities on cost-effectiveness results. By using accuracy
estimates drawn from enrollees in a single large US study, we
providedmoredirect comparisons of all strategies in sensitiv-
ity analyses.We also followed detailed contemporary clinical
algorithmsandadjustedboth sensitivity and specificity in the
surveillance and posttreatment settings to more accurately
Figure 2. Probability of Each Strategy Being Cost-effective at Various Cost-effectiveness Thresholds
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reflect thebenefits, harms, and costs incurred throughout the
full trajectory of recommended care in the United States.
Conclusions
Without quality adjustments, conferred life-years
varied little among all 12 screening strategies (29.54175-
29.54523 life-years; Figure 1), a finding that underscores
the importance of quantifying screening harms and
costs unique to each strategy. Identifying and promoting
strategies that maximize quality of life outcomes and
minimize costs at all steps throughout the screening
process will provide higher-value cervical cancer screening
from the perspectives of society, the health care sector,
and women.
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